Boxer Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Boxer Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,287,782	Closed	-$43.7M	–	86
2021 Q3	$43.7M	Hold	2,287,782	–	–	1.53%	16
2021 Q2	$39.3M	Hold	2,287,782	–	–	1.39%	21
2021 Q1	$51.2M	Hold	2,287,782	–	–	1.73%	13
2020 Q4	$50.9M	Hold	2,287,782	–	–	1.64%	17
2020 Q3	$33.8M	Hold	2,287,782	–	–	1.17%	20
2020 Q2	$33.9M	Buy	2,287,782 +1,562,000	+215%	+$23.8M	1.49%	21
2020 Q1	$7.96M	Buy	725,782 +475,782	+190%	+$4.46M	0.54%	42
2019 Q4	$2.19M	Sell	250,000 -150,000	-38%	-$1.1M	0.12%	50
2019 Q3	$2.99M	Buy	+400,000	New	+$3.64M	0.22%	42
2018 Q4	–	Sell	-100,000	Closed	-$808K	–	27
2018 Q3	$808K	Hold	100,000	–	–	0.09%	24
2018 Q2	$702K	Hold	100,000	–	–	0.08%	26
2018 Q1	$1.42M	Hold	100,000	–	–	0.15%	31
2017 Q4	$876K	Hold	100,000	–	–	0.16%	25
2017 Q3	$1.17M	Sell	100,000 -134,220	-57%	-$1.65M	0.27%	27
2017 Q2	$3.27M	Hold	234,220	–	–	0.78%	19
2017 Q1	$3.21M	Hold	234,220	–	–	0.7%	20
2016 Q4	$1.68M	Hold	234,220	–	–	0.65%	18
2016 Q3	$3.55M	Hold	234,220	–	–	1.59%	15
2016 Q2	$2.31M	Hold	234,220	–	–	2.05%	14
2016 Q1	$3.12M	Buy	+234,220	New	+$2.94M	3.05%	10

Other funds holding SNDX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boxer Capital's SNDX Position: Q4 2021 in Review

Boxer Capital sold out of Syndax Pharmaceuticals (SNDX) in Q4 2021, closing a stake of 2,287,782 shares — an estimated $43.7M sold.

Boxer Capital first reported a position in SNDX in Q1 2016 and held it in 20 quarters. The position peaked at $51.2M in Q1 2021. 132 funds tracked by Wall St. Rank hold SNDX as of Q4 2021.

Boxer Capital reported no remaining Syndax Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Boxer Capital sold 2,287,782 Syndax Pharmaceuticals shares in Q4 2021, an estimated $43.7M.
Boxer Capital first reported a position in Syndax Pharmaceuticals in Q1 2016 and held it in 20 quarters.
Boxer Capital's Syndax Pharmaceuticals position peaked at $51.2M in Q1 2021.
132 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2021.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.